575 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Medicine type
Additional monitoring Remove Additional monitoring filter
Generic Remove Generic filter
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Briviact (in Italy: Nubriveo) (updated)
Brivaracetam, Epilepsy
Date of authorisation: 13/01/2016,
, Revision: 8, Authorised, Last updated: 27/03/2020
-
List item
Human medicine European public assessment report (EPAR): Veyvondi (updated)
vonicog alfa, von Willebrand Diseases
Date of authorisation: 31/08/2018,, Revision: 1, Authorised, Last updated: 27/03/2020
-
List item
Human medicine European public assessment report (EPAR): Gazyvaro (updated)
Obinutuzumab, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 22/07/2014,, 
, Revision: 9, Authorised, Last updated: 26/03/2020
-
List item
Human medicine European public assessment report (EPAR): Dovato (updated)
dolutegravir sodium, lamivudine, HIV Infections
Date of authorisation: 01/07/2019,, Revision: 1, Authorised, Last updated: 26/03/2020
-
List item
Human medicine European public assessment report (EPAR): Pazenir (updated)
paclitaxel, Breast Neoplasms
Date of authorisation: 06/05/2019,
, Revision: 4, Authorised, Last updated: 25/03/2020
-
List item
Human medicine European public assessment report (EPAR): Lojuxta (updated)
Lomitapide, Hypercholesterolemia
Date of authorisation: 31/07/2013,, 
, Revision: 12, Authorised, Last updated: 25/03/2020
-
List item
Human medicine European public assessment report (EPAR): Prevymis (updated)
Letermovir, Cytomegalovirus Infections
Date of authorisation: 08/01/2018,, , Revision: 6, Authorised, Last updated: 25/03/2020
-
List item
Human medicine European public assessment report (EPAR): Takhzyro (updated)
lanadelumab, Angioedemas, Hereditary
Date of authorisation: 22/11/2018,, 
, , Revision: 2, Authorised, Last updated: 25/03/2020
-
List item
Human medicine European public assessment report (EPAR): Mysimba (updated)
bupropion hydrochloride, naltrexone hydrochloride, Obesity, Overweight
Date of authorisation: 26/03/2015,, Revision: 15, Authorised, Last updated: 25/03/2020
-
List item
Human medicine European public assessment report (EPAR): Kromeya (updated)
adalimumab, Arthritis, Rheumatoid, Arthritis, Juvenile Rheumatoid, Psoriasis, Arthritis, Psoriatic, Spondylitis, Ankylosing, Uveitis, Colitis, Ulcerative, Crohn Disease
Date of authorisation: 02/04/2019,, 
, Revision: 4, Withdrawn, Last updated: 25/03/2020
-
List item
Human medicine European public assessment report (EPAR): Zalasta (updated)
olanzapine, Schizophrenia, Bipolar Disorder
Date of authorisation: 27/09/2007,, Revision: 17, Authorised, Last updated: 25/03/2020
-
List item
Human medicine European public assessment report (EPAR): Vaxelis (updated)
Diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens: pertussis toxoid, filamentous haemagglutinin, pertactin, fimbriae Types 2 and 3, hepatitis B surface antigen produced in yeast cells, poliovirus (inactivated): type 1 (Mahoney), type 2 (MEF-1), type 3 (Saukett) produced in Vero cells/ Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to meningococcal protein., Meningitis, Haemophilus, Poliomyelitis, Tetanus, Diphtheria, Whooping Cough, Hepatitis B
Date of authorisation: 15/02/2016,, Revision: 7, Authorised, Last updated: 25/03/2020
-
List item
Human medicine European public assessment report (EPAR): Mayzent (updated)
Siponimod fumaric acid, Multiple Sclerosis, Relapsing-Remitting
Date of authorisation: 13/01/2020,, Revision: 1, Authorised, Last updated: 24/03/2020
-
List item
Human medicine European public assessment report (EPAR): Kisqali (updated)
ribociclib succinate, Breast Neoplasms
Date of authorisation: 22/08/2017,, Revision: 3, Authorised, Last updated: 24/03/2020
-
List item
Human medicine European public assessment report (EPAR): Suliqua (updated)
insulin glargine, lixisenatide, Diabetes Mellitus, Type 2
Date of authorisation: 11/01/2017,, Revision: 5, Authorised, Last updated: 24/03/2020
-
List item
Human medicine European public assessment report (EPAR): Biktarvy (updated)
bictegravir, emtricitabine, tenofovir alafenamide, fumarate, HIV Infections
Date of authorisation: 21/06/2018,, Revision: 5, Authorised, Last updated: 24/03/2020
-
List item
Human medicine European public assessment report (EPAR): Levetiracetam Actavis (updated)
levetiracetam, Epilepsy
Date of authorisation: 03/10/2011,, Revision: 15, Authorised, Last updated: 24/03/2020
-
List item
Human medicine European public assessment report (EPAR): Aripiprazole Accord (updated)
aripiprazole, Schizophrenia, Bipolar Disorder
Date of authorisation: 15/11/2015,, Revision: 9, Authorised, Last updated: 24/03/2020
-
List item
Human medicine European public assessment report (EPAR): Trazimera (updated)
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 26/07/2018,, , Revision: 5, Authorised, Last updated: 24/03/2020
-
List item
Human medicine European public assessment report (EPAR): Insulin lispro Sanofi (updated)
insulin lispro, Diabetes Mellitus
Date of authorisation: 18/07/2017,, , Revision: 5, Authorised, Last updated: 24/03/2020
-
List item
Human medicine European public assessment report (EPAR): Trogarzo (updated)
Ibalizumab, HIV Infections
Date of authorisation: 26/09/2019,, Revision: 1, Authorised, Last updated: 23/03/2020
-
List item
Human medicine European public assessment report (EPAR): Atriance (updated)
nelarabine, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 22/08/2007,, , Revision: 23, Authorised, Last updated: 23/03/2020
-
List item
Human medicine European public assessment report (EPAR): Cresemba (updated)
isavuconazole, Aspergillosis
Date of authorisation: 15/10/2015,, , Revision: 8, Authorised, Last updated: 23/03/2020
-
List item
Human medicine European public assessment report (EPAR): Ambrisentan Mylan (updated)
ambrisentan, Hypertension, Pulmonary
Date of authorisation: 20/06/2019,, Revision: 1, Authorised, Last updated: 20/03/2020
-
List item
Human medicine European public assessment report (EPAR): Imraldi (updated)
adalimumab, Hidradenitis Suppurativa, Psoriasis, Crohn Disease, Uveitis, Arthritis, Rheumatoid, Arthritis, Colitis, Ulcerative, Spondylitis, Ankylosing, Arthritis, Psoriatic
Date of authorisation: 24/08/2017,, , Revision: 11, Authorised, Last updated: 20/03/2020